Infectious Disease Diagnostic Testing: World Market Analysis of TB, Flu, HIV, Hepatitis, Strep A, Malaria, HPV, Blood Screening, STDs, ID/AST, HAI, Rapids and Other Test Products

 
   Single User - $5,500
   Site License (one location, 10 users) - $8,250
   Corporate License - $11,000



Loading...
Published Feb 26, 2018 | 325 Pages | Pub ID: KLI15607955

Nearly a third of the revenues earned from clinical testing products are earned from products that detect infectious diseases

Despite this enormous size, the market remains dynamic.  It's also a global market: the entire world prioritizes infectious disease in its healthcare provision.  Indeed, the demand to detect and counter infectious disease threats has helped launch new technologies such as molecular systems and point of care, PCR-alternative molecular amplification methods, next-generation sequencing (NGS), microarrays and other technologies.  Infectious disease testing offers a mix of some mature segments with rapid spikes in market growth in the infectious disease test market can occur with the emergence of new disease threats or acceptance of new routine screening procedures.   

Key segments include TB, Flu, HIV, Hepatitis, Strep A, Malaria, HPV, Blood Screening, STDs, ID/AST, Rapids, HAI and Other Test Products

Kalorama Information's new report, The World Market for Infectious Disease Diagnostics: World Market Analysis, is designed to provide a total picture of the market for products that test for infectious diseases to aid clinical decisions.  Readers will benefit from a complete world country analysis, with major country markets defined for each segment, a total of 348 market tables provided.  The enhanced segmentation allows for better business planning and market opportunity sizing.  


25-Country and Region Market Analysis with over 340 Tables

Managed care in the United States and other developed countries demands quicker and more specific test results for infectious diseases. Rapid, near-patient testing can be used to rationalize antimicrobial usage and reduce repeat physician office visits. However, cost improvements are needed to widen the role of test products used in POC and POL settings as decentralized testing is disproportionately affected by cuts to reimbursements and pricing pressure on laboratory services and diagnostic procedures. 

Infectious Disease Diagnostic Testing: World Market Analysis  covers 30 areas of infectious diseases.   Diseases and technology categories covered in this report include:

Blood Screening Immunoassay 
Blood Screening NAT  
Influenza Tests 
Strep A Test
RSV Testing
Malaria Tests 
Dengue Testing  
HIV Tests – Laboratories
HIV Tests – POC
Hepatitis Testing, Lab-Based
Hepatitis Testing, POC 
STD Testing
HPV Testing
TORCH Testing
TB Labs 
TB POC 
ID/AST Market, Auto
ID/AST, Manual 
Blood Culture
Chromogenic Media
Rapid Micro
Sepsis  
MRSA 
C. diff 
VRE 
Other HAI  
Parasitology
Mycology 
Emerging Infectious Disease Tests
Home OTC
Other

Advancements in instrument automated analysis and microfluidics have allowed for the proliferation of infectious disease testing across settings and institutions – from traditional sites such as reference labs through physician office laboratories (POLs) and mobile clinics in the developing world.   For each of these product segments, the report provides a market size and forecast 2017-2025 for the following countries:

United States
Canada
Germany
France
Spain
UK
Italy
Other Europe
Australia
Japan
China
Eastern Europe
South Africa
Indonesia
Malaysia
Singapore
India
Saudi Arabia
Turkey
Russia
Taiwan
South Korea
Brazil
Chile
Columbia
Other LATAM
ROW


In addition, the report provides:
 
Global Market Sizing 
Forecasts to 2025
Company Profiles of Infectious Disease Testing providers
Assessment of Trends
Overview of Types of Testing
Breakout by testing technology (molecular, immunoassay) for Hepatitis and HIV
Breakout by POC vs. lab-test by technology (Hepatitis, HIV, TB, other)


Increased funding for infectious disease diagnostics from international governmental, non-governmental and non-profit health organizations is assisting in the development of a new generation of sophisticated test platforms designed to meet the needs of testing in low-resource environments (electricity, water, refrigeration, other environmental control, and personnel).

Payers in the industrialized world are being encouraged and have been receptive to increased coverage of infectious disease testing and screening. While preventive testing services are traditionally associated with “lifestyle” or non-communicable diseases, infectious disease tests also strongly qualify under preventive services. Latent or asymptomatic diseases can progress into severe chronic conditions that challenge healthcare funding and contribute significantly to national healthcare spending. Increasingly sensitive and accurate infectious disease diagnostics are crucial to implementing therapy earlier in the infection and avoiding higher costs of treatment.

Public health officials worldwide have begun to recognize the global nature of infectious diseases – they are no longer a problem of developing countries but touch the very fabric of the social and economic welfare of countries in the industrialized world as well. The globalized world market has exposed far-apart populations to the burdens of infectious disease and exacerbated disease outbreaks. The potential for the re-introduction of eradicated or controlled infectious diseases is higher than ever. Pathogen drug resistance, in particular, is a problem throughout the world and will require a global response.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.